Eplontersen Trial Fails to Meet Primary Endpoint in Transthyretin Amyloid Cardiomyopathy
Source Summary
The CARDIO-TTRansform trial of eplontersen in patients with transthyretin-mediated amyloid cardiomyopathy failed to meet its primary efficacy endpoint. Results were presented in a Hot Line session at ESC Congress 2026.
Why it matters
The failure to meet the primary endpoint indicates that eplontersen did not demonstrate the expected efficacy in this patient population with a serious cardiac condition.
